Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab versus Placebo
2013-001119-54Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Solanezumab with Placebo (2 arms). Primary endpoint: ADAS-Cog14. Started May 2013; status: terminated.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2013-001119-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001119-54.